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Abstract  
 
Hyperkinetic movement disorders represent a heterogeneous group of disorders in which 
involuntary movements are the prevalent clinical symptoms. The five main categories of 
hyperkinetic disorders are tremor, dystonia, tics, myoclonus and drug-induced dyskinesia. 
The severity of hyperkinetic disorders is assessed by all clinicians when they examine a 
patient; quantifying the severity also provides a means of studying the natural history of a 
given disorder and the possible effect of new therapeutic interventions. This means that 
good rating instruments are required in both everyday practice and experimental settings. 
Unfortunately, the clinical evaluation of these disorders is complicated by the inherent 
nature and variability over time of involuntary movements. A number of scales have been 
proposed over the years to study the various hyperkinetic disorders. The aim of this review 
is to systematically identify all the clinical scales that have been proposed and to classify 
them according to the criteria developed by the Movement Disorder Society (MDS) task 
force for rating scales in PD. On the basis of this methodology, a scale may be defined as 
‘Recommended’, ‘Suggested’ or ‘Listed’ in decreasing order of value. 
We found that, although numerous scales aimed at assessing hyperkinetic disorders have 
been published, their variability in terms of clinimetric properties, availability and effort 
required to administer them is high. In this evaluation, we identified scales defined as 
‘Recommended’ for the assessment of all forms of hyperkinetic disorders. The situation 
highlighted by our analysis varies considerably, with several ‘Recommended’ scales being 
available for some conditions such as tics or dystonia, but only one being available for 
myoclonus. This gap needs to be filled by the scientific community through both the 
development of new clinical tools and the refinement of existing ones.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
Introduction 
 
 
Hyperkinetic movement disorders represent a heterogeneous group of disorders in which 
unwanted (involuntary) movements are the prevalent clinical symptoms. These disorders are 
usually linked to basal ganglia dysfunction (Abdo et al, 2010). The five main categories of 
dyskinesia are tremor, dystonia, tics, myoclonus and drug-induced dyskinesia. 
The severity of hyperkinetic disorders is assessed by all clinicians when they examine a 
patient. Quantifying the severity also provides a means of studying the natural history of a 
given disorder and the possible effect of new therapeutic interventions. In recent decades, a 
number of mechanical and electronic devices, including accelerometers, have been 
developed jointly by physicians and engineers to measure involuntary movements; more 
recently, computerized devices have also been designed (Mansur et al, 2007). The 
advantages of mechanical and electronic measurements are objectivity and consistency even 
when they are performed by different clinicians. However, as these measurements do not 
appear be as sensitive as clinical measurements, hyperkinetic disorders continue to be 
assessed largely by clinical methods. This means that good rating instruments are required in 
both everyday practice and experimental settings. Unfortunately, the clinical evaluation of 
these disorders is complicated by the inherent nature and variability over time of involuntary 
movements. A number of scales have been proposed over the years to study the various 
hyperkinetic disorders. The aim of this review is to systematically identify all the clinical 
scales that have been proposed and to classify them according to the criteria developed by 
the Movement Disorder Society (MDS) task force for rating scales in Parkinson’s Disease 
(PD) (Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, 
2003). The systematic review of the PD rating scales carried out by this task force was 
conducted according to an established methodology (Goetz et al, 2008). This process 
includes scale identification, selection and appraisal strategies, using terminology and 
definitions developed ad hoc (Goetz et al, 2008) . On the basis of this methodology, a scale 
is defined as ‘Recommended’ if it has been applied to that specific disease population, if 
there are data on its use in studies other than those collected by the group that developed the 
scale, and if it has been studied clinimetrically and found to be valid, reliable and sensitive 
to change. A scale is defined as ‘Suggested’ if it has been applied to specific populations, 
but only one of the other criteria applies. A scale is defined simply as ‘Listed’ if it satisfies 
only one of the three criteria used to define ‘Recommended’ scales. Owing to the relative 
lack of proven treatments for hyperkinetic disorders, the clinimetric criterion for rating 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
dyskinesia scales does not categorically require responsiveness to be established. Indeed, if a 
scale fulfills the requirements of reliability and validity, the criterion is considered to be 
satisfied, although the absence of responsiveness is noted as a weakness of that scale. This 
classification has been successfully used to assess the validity of the scales used for both 
motor and non-motor aspects of PD (Colosimo et al, 2010).  
This review will follow the same pattern for each one of the conditions studied. Only 
published or in press peer-reviewed papers or published abstracts form main neurological 
meetings were evaluated. The Medline database on PubMed was searched for relevant 
papers and all the scales used to measure a given disorder were identified (as of Medline last 
accessed on the 10
th
 of November 2014)  using the following query: ‘’Hyperkinetic 
disorders’’ AND ‘Assessment’ OR ‘Scales’ OR ‘Questionnaires’. For each scale, a search 
was conducted for the following terms  ‘Tremor’ AND ‘Assessment’ OR ‘Scales’ OR 
‘Questionnaires’, ‘Dystonia’ AND ‘Assessment’ OR  ‘Scales’ OR ‘Questionnaires’, 
‘Chorea’ AND ‘Assessment’ OR ‘Scales’ OR ‘Questionnaires’, ‘Tics’ AND ‘Assessment’ 
OR ‘scales’ OR ‘Questionnaires’, ‘Myoclonus’ AND ‘assessment’ OR ‘scales’ OR 
‘Questionnaires’, ‘Drug-induced dyskinesias’ AND ‘Assessment’ OR ‘Scales’ OR 
‘Questionnaires’. In addition for each scale, a search was conducted for the terms ‘Tremor’, 
‘Dystonia’, ‘Chorea’, ‘Tics’, ‘Myoclonus’, ‘Drug induced dyskinesias’ and the name of the 
scale. All scales have been reported in a specific table, though only those defined as 
‘Recommended’ according to the aforementioned criteria will be appraised and discussed in 
detail in the following text.  
 
 
Tremor 
 
Twelve scales have been assessed for tremor evaluation (Fahn et al, 1993; Bain et al, 1993; 
Louis et al, 1997, Elbe et al, 2012; Jankovich et al, 1996; Bove’ et al, 2006; Sweet et al, 
1974; Findley et al, 1985; Koller et al, 1989; Jefferson et al, 1979; Baruzzi et al, 1983; 
Ogawa et al, 1987) (Table 1), but only two of them, the Fahn-Tolosa-Marin Tremor rating 
scale (FTM-TRS) and the Washington Heights-Inwood Genetic Study of Essential Tremor 
(WHIGET), reached recommendation status (Table 2). 
 
 
Fahn-Tolosa-Marin Tremor rating scale 
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Scale description 
 
The Tremor Rating Scale (TRS) was developed by Fahn, Tolosa and Marin to quantify rest, 
postural and action/intention tremors (Fahn et al, 1993). This scale also evaluates voice 
tremor as well as handwriting and other tasks, such as hygiene and dressing, assessing the 
impact of tremor on patients’ daily life. The TRS is divided into three parts (A, B and C), 
yielding a subtotal score that can be combined in an overall TRS score. Part A (scores 1-10) 
quantifies tremor at rest, with posture holding, and performing an activity, for nine parts of 
the body (face, tongue, voice, head, upper and lower limbs and trunk), and orthostatic 
tremor. Severity of tremor is rated by amplitude on a 5-point scale. Part B (scores 1-15) 
relates to action tremors of the upper extremities, particularly writing and pouring liquids. 
Drawing tasks require Archimedes’ spirals (two types) and draw a straight line between 
narrow confine (three times). Writing and drawing tremor are scored on a 5-point scale 
where pouring water from one cup to another is also quantified. Cup size and the amount of 
water used in the test are specified. Part C assesses functional disability. Its items evaluated 
the severity of tremor with speaking, eating (feeding), bringing liquids to the mouth, 
hygienic care, dressing, working, including domestic tasks, and social activities. These 
scores, with the exception of speaking, are provided  by patients, who are asked to evaluated 
their ability to carry out these tasks by using provided definitions (score 0 to 4). The 
maximum possible scores are 88 for part A, 36 for part B and 32 for part C, making the 
maximum possible total score of 156. Finally, in addition to the quantification of tremor in 
parts A, B, and C, the scoring form allows assessment of overall severity by both the patient 
and the examiner (global assessment) on a 5-point scale (0 to 4).  
 
Key evaluation issues  
 
The interrater and intrarater reliability were evaluated for part A and B (excluding pouring 
water) in Essential Tremor (ET) patients (Stacy et al, 2007). This evaluation revealed fair 
(part A; modified Kappa ranging from 0.53-0.62) to poor (part B; modified Kappa ranging 
from 0.17-0.41) interrater reliability. Intrarater reliability calculated with Spearman’s 
correlation, indicated a good consistency (overall Spearman’s correlation= 0.87), although 
still not as good for part B. Inter and intrarater reliability were separated assessed for 
neurologists and non-neurologists, showing a lower consistency for the latters. Interrater 
reliability was also measured in patients with Multiple Sclerosis tremor (Hooper et al, 1998), 
showing a reliability coefficients ranging from 0.69 to 0.99, calculated via Kendall’s 
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coefficient of concordance to determine overall agreement. The intrarater reliability 
coefficients (Spearman’s correlation coefficient) ranged from 0.85 to 0.97 for the different 
categories of head tremor, 0.64 to 0.93 for trunk tremor, 0.92 to 0.99 for the right upper limb 
tremor, 0.81 to 0.99 for the left upper limb tremor, and 0.87 to 1 for the tremor evident when 
performing upper limb tasks (spiralography and volumetric test). Levels of reliability were 
high except when certain categories of tremor in the trunk were assessed (postural tremor r = 
0.64 and goal related r = 0.72). 
 
Strengths and Weaknesses 
 
The scale appears very similar to another scale to assess tremor, designed by the Tremor 
Investigation Group: the UTRA scale (Unified Tremor Rating and Assessment, 6). In fact, 
the TRS was developed incorporating some items used in the UTRA scale to writing and 
drawing tasks and to the assessment of functional disability. It showed fair-to-poor 
concordance between raters, especially for non-neurologist, and good intrarater reliability in 
repeat assessment, although not as good for part B. The scale provides specific instructions 
to standardize the evaluations, specific definitions for tremor severity assessment and words 
anchors for the scores. It is a quite complex instrument requiring some time for its use, and 
can be repeated over time.  
 
Washington Heights-Inwood Genetic Study of Essential Tremor rating scale 
 
Scale description 
 
The Washington Heights-Inwood Genetic Study of Essential Tremor (WHIGET) scale was 
developed for a community-study on ET (Louis et al, 1997). It is a detailed examination of 
upper limbs tremor that incorporate multiple test items, in addition to writing and a clinical 
rating scale. The WHIGET tremor rating scale consists of a six-test 10-minute tremor 
examination designed to elicit rest tremor (two  positions), postural tremor (one test: 
sustained arm extension), and kinetic tremor (five tests: pouring water between two cups, 
drinking water from a cup, using a spoon to drink water, finger-to-nose movements, and 
drawing Archimedes spirals). Each task is first performed with the dominant arm and then 
with the nondominant arm. The ratings are as follows: 0= no visible tremor, 1= a low 
amplitude tremor that is barely perceivable or is intermittent, 2= tremor that fulfils three 
criteria: moderate amplitude and usually present and clearly oscillatory (clearly varies 
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between alternate extremes with a definable period), and 3= large amplitude, jerky tremor 
resulting in spilling, and difficulty hitting a target. For kinetic tremor, a rating of 4 was 
subsequently added to broaden the applicability of this scale to clinical trials. This new 
rating signified an extremely large amplitude, jerky kinetic tremor resulting in inability to 
handle liquids, reluctance to touch finger to nose because of fear of self-injury, or inability to 
draw a spiral. The WHIGET performance-based test of function is a 15-items, 10-minute test 
developed for the “Columbia University Assessment of Disability In Essential Tremor” 
study. Each task is performed with the dominant arm and rated according to a 0-to-4 point 
rating scale (0= no difficulty; 1= mild difficulty; 2= moderate difficulty; 3= severe difficulty; 
4= unable to perform the task). A shorter 6-item 5-minute version was also proposed, 
containing activities that are frequently performed: place keys in lock, drink from a glass, 
copy sentences, place bills in wallet, dial number on telephone, place coins in slot.   
 
 Key evaluation issues   
 
Inter-rater agreement for this scale was assessed in ratings of postural and kinetic tremor 
(weighted kappa= 0.62–0.78) (Louis et al, 1998). There was also a high degree of test–retest 
stability when the two neurologists rated tremor at two separate time intervals (r = 0.98, P < 
0.00001) as well as high validity (Louis et al, 1998). A teaching videotape was then 
developed, accompanied by written instructions. Inter-rater reliability was assessed in raters, 
after viewing this teaching videotape, for five of the six test items (drawing a spiral, pouring, 
sustained arm extension, drinking, finger-to-nose maneuver), agreement among raters was 
nearly perfect or perfect (weighted kappa= 0.86-1), and for the sixth (using a spoon), it was 
substantial (weighted kappa= 0.79) (Louis et al, 2001). The validity of the 15-item WHIGET 
performance-based test was tested among ET cases (Louis et al, 1999). The total score of the 
scale correlated with the total number of questions answered yes (r=0.44;P=0.001) of a 
validated 12-items screening questionnaire for ET (Louis et al, 1998); the total score of a 31-
item tremor disability questionnaire to assess the functional impact of tremor (Fried et al, 
1996). However, before the registration of this videotape, the WHIGET Tremor Rating Scale 
was revised (adding a score of 4 for kinetic tremor), and it cannot be assumed that the intra-
rater reliability and validity of the revised scale is identical to those of the original version. A 
correlation with this scale to a quantitative measure (motion sensor) showed a good 
correlation for postural (r=0.90) and kinetic (r=0.80) tremors in ET patients.  
 
Strengths and weaknesses 
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The WHIGET are all easily administered, simple, and user friendly, requiring 10 minutes 
each (5 minutes the WHIGET performance-based scale containing 6 items). Clinimetric 
properties were assessed and appeared good, demonstrating a good validity, consistency and 
reproducibility. However, the performance-test scale assess only dominant-arm functions 
and is influences by kinetic tremor, ignoring tremor in other body parts (nondominant arm, 
legs, head, voice) and rest and postural tremor. WHIGET has been used by the same authors 
and by others groups in a prevalence survey on ET (Sur et al, 2009) and in a pilot study on 
memantine treatment for ET (Handforth, 2010). 
 
 
Dystonia 
 
Thirty scales have been assessed for evaluation of different types of dystonia (Jankovic et al, 
2009; Cano et al, 2004; Consky et al, 1994; Muller et al, 2004; Jacobson et al, 1997; Carding 
et al, 1999, Burke et al, 1985; Troung et al, 2013; Lindeboomet al, 1995; Page et al, 2007;  
Tsui et al, 1985, 1986, 1987; Fernandez et al, 2013; Münchau et al, 2001, Merz et al, 2010; 
Stewart et al, 1997; Morzaria et al, 2012; Jabush et al, 2004; Priori et al, 2001; Comella et al, 
2003) (Table 3). Seven of them, the Blepharospasm Disability Index (BDI),  the Cervical 
Dystonia Impact Scale, the Toronto Western Spasmodic Torticollis Rating Scale, the  
Craniocervical Dystonia Questionnaire (CDIS), the Voice Handicap Index (VHI), the Vocal 
Performance Questionnaire (VPQ) and the Fahn-Marsden Dystonia Rating Scale (FMDRS), 
reached the recommendation status (Albanese et al, 2013) (Table 4). 
 
 
 
Blepharospasm Disability Index 
 
Scale description 
 
The Blepharospasm Disability Index (BSDI) (Jankovic et al, 2009) was developed to 
improve the Blepharospasm Disability Scale  It consists of 6 items rating specified activities 
(vehicle driving, reading, watching television, shopping, walking, and doing everyday 
activities), scored as a 5-point Likert scale relating to the severity of impairment (0, no 
impairment; 4, no longer possible due to illness). The range of scores is 0 to 24, with higher 
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scores indicating a greater disability. 
 
 Key evaluation issues   
 
The BSDI showed high internal consistency and the retest reliability of the single items was 
adequate (Jankovic et al, 2009). 
 
Strengths and Weaknesses 
 
The scale focuses on daily activities and is easy to use; the scoring system is also rather 
simple. The BSDI focuses on disability related to sight and does not specifically measure 
dystonic motor abnormalities. Concern has been raised regarding poor sensitivity of the 
scale to mild disability for small changes. 
 
Cervical Dystonia Impact Scale 
 
Scale description.  
 
This scale is composed of 58 five-point items grouped into 8 subscales that measure 
symptoms (head and neck movements, pain and discomfort in neck and shoulders, sleep 
disturbance as a result of torticollis), activity limitations in upper limb activities and 
walking, and psychosocial features (annoyance, mood, psychosocial functioning). Eight 
summary scale scores are generated by summing items and are then transformed to a 0 to 
100 score 
 
Key issues   
 
New psychometric techniques (Rasch analyses) revealed that the CDIP-58 performs well 
and, in addition, traditional psychometric properties such as reliability (internal consistency, 
item-total correlation, test-retest) and validity have been supported (Cano et al, 2006; 
Zetterberg et al, 2009; Cano et al, 2008).   
 
Strengths and Weaknesses 
 
The CDIP-58 is a disease specific validated questionnaire. It is more sensitive in detecting 
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statistical and clinical changes than comparable subscales. 
 
Toronto Western Spasmodic Torticollis Rating Scale 
 
Scale description 
 
The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS is composed of 3 
subscales that measure symptom severity, disability, and pain. The clinician-rated severity 
scale is composed of 11 items that assess head movements, duration of symptoms, effects of 
sensory tricks, shoulder elevation and anterior displacement, range of motion, and time in 
neutral position; the maximal score is 35. The disability scale, patient-rated, comprises 6 
items, including daily activities, work, reading, and driving; the maximal score is 30. The 
pain scale, patient-rated, comprises 3 items including severity, duration, and disability due to 
pain; the maximal score is 20. Each subscale is scored as refinement of the walking subscale 
independently and a total TWSTRS score (from 0 to 85) is calculated. 
 
 Key evaluation issues   
 
The TWSTRS has been widely used (Münchau et al, 2001), and has been shown to have 
internal consistency and acceptable interrater agreement. Evidence for validity is shown by 
moderate within-scale correlations (Consky and Lang, 1994). Responsiveness to change has 
been demonstrated (Comella et al, 2011;  Lew et al, 2010). 
 
Strengths and Weaknesses 
 
The TWSTRS assesses the severity of cervical dystonia and includes disability interrater 
agreement. Evidence for validity is shown by moderate within-scale correlations (Consky 
and Lang, 1994). Responsiveness to change has been demonstrated (Comella et al, 2011; 
Lew et al, 2010). The TWSTRS scale might be too complex for routine clinical practice. A 
revised version of the TWSTRS has been recently devised and its clinimetric properties are 
at the moment under scrutiny (Comella, personal communication). 
 
Craniocervical Dystonia Questionnaire 
 
Scale description 
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The Craniocervical Dystonia Questionnaire (CDQ-24) is composed of 24 items, forming 5 
subscales: stigma, emotional well-being, pain, activities of daily living, and social/family 
life. Items are rated on a 5-point scale.  
 
 
 Key evaluation issues   
 
The CDQ-24 showed good reliability properties, internal consistency, and test-retest 
reliability. Validity was assessed by checking convergent and discriminant validity as well as 
the dimensional structure of CDQ-24; sensitivity to change was confirmed after BoNT 
treatment (Muller et al, 2004).  
 
Strengths and Weaknesses 
 
The CDQ-24 is an easy instrument and also evaluates pain, sleep, and depression due to 
dystonia. 
 
Voice Handicap Index 
 
Scale description 
 
The Voice Handicap Index (VHI) has 30 items organized in 3 domains: a 10-item functional 
subscale, a 10-item emotional subscale, and a 10-item physical subscale. The rating is on a 
5-point scale and the total score ranges from 0 to 120.  
 
 Key evaluation issues   
 
The VHI proved to have good internal consistency and good test-retest reliability for 
subscales and total scores. Construct validity was not fully evaluated. The VHI has been 
used in several studies to assess efficacy of treatments for laryngeal dystonia. 
 
Strengths and Weaknesses 
 
The VHI is a simple and efficient scale, but as a disability scale, it has no discriminant value 
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and is not specific for dystonia. The VHI is similar to the Vocal Performance Questionnaire, 
and direct comparisons have been made showing similar clinimetric properties. 
 
Vocal Performance Questionnaire 
 
Scale description 
 
This scale was designed for use in an evaluation study of voice therapy in cases of 
nonorganic dysphonia (Carding et al, 1999) The Vocal Performance Questionnaire (VPQ) is 
a 12-item questionnaire designed using an answer format in which the patient selects the 
statement that best answers each question. The statements are graded in terms of severity of 
vocal performance.  
 
 Key evaluation issues   
 
The VPQ was initially found to have good internal consistency in a study that included a 
large range of voice pathologies except for spasmodic dysphonia (Deary et al, 2004). In a 
study that included patients with laryngeal dystonia, (Webb et al, 2007) the VPQ had high 
levels of internal consistency and test-retest reliability. Although the VPQ still needs further 
validation in patients with organic disorders, it may be Recommended for use in laryngeal 
dystonia. 
 
Strengths and Weaknesses 
 
The VPQ is a simple and efficient scale, but as a disability scale, it has no discriminant value 
and is not specific for organic dystonia.  
 
 
Fahn-Marsden Dystonia Rating Scale 
 
Scale description.  
 
The Fahn-Marsden Dystonia Rating Scale (FMDRS) is composed of 2 clinician rated 
subscales: a movement subscale, based on patient examination, and a disability subscale, 
based on the patient’s report of disability in activities of daily living. The movement 
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subscale rates dystonia severity and provoking factors in 9 body areas, including eyes, 
mouth, speech and swallowing, neck, trunk, and both arms and legs. All items have a 5-point 
score. The provoking factor rates the relation of dystonia to action, from 0 (no dystonia at 
rest or with action) to 4 (dystonia at rest). The scores obtained for eyes, mouth, and neck are 
each multiplied by 0.5, before being entered into the calculation of the total score, in order to 
down-weight them. The total movement FMDRS subscore is provided by the sum of the 
products of the provoking, severity, and weighting factors. The maximal total FMDRS score 
is 120. The disability subscale is composed of 7 items for activities of daily living, such as 
speech, writing, feeding, eating, hygiene, dressing, and walking. These are rated on a 5-point 
score (with the exception of walking, which is rated on a 7-point score), providing a 
maximum disability subscore of 30. 
 
 Key evaluation issues   
 
 In the original validation study the reliability, interrater agreement, and concurrent validity 
of the FMDRS were demonstrated for the total score without reporting the level of 
agreement for ratings of the different body regions (Burke et al, 1985) The FMDRS showed 
good internal consistency and good level of interrater reliability for the total scores (Comella 
et al, 2003) For separate items, interrater agreement was fair to good, being lowest for eyes, 
jaw, face, and larynx (Comella et al, 2003). 
 
Strengths and Weaknesses 
 
Limitations in the FMDRS include a weighting factor that halves the contribution of 
dystonia in eyes, mouth, and neck to the total score. The FMDRS does not assesses in detail 
the individual body areas, such as separate ratings for proximal and distal limbs; moreover, 
included in the FMDRS there is a subjective patient rating for speech and swallowing. 
 
Chorea 
 
There are many causes of chorea, but scales have been mainly developed for the disease that 
represents the prototype of choreatic disorders, Huntington's disease (HD). The only 
exception is a scale specifically developed for Sydenham’s chorea (Teixeira et al, 2005), the 
USCRS, which has not been employed by research groups outside the one that proposed it. 
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Four scales have been identified that are used to assess HD (Huntington Disease Study 
Group, 1996; Guy, 1976; Marsden and Schachter, 1981) (Table 5), of which three reached 
the Recommended status (Table 6). These three scales, the Unified Huntington's Disease 
Rating Scale (UHDRS), the
 
Abnormal Involuntary Movement Scale (AIMS), and the 
modified motor score of the UHDRS (mMS), will be discussed here in detail. 
 
Unified Huntington’s Disease Rating Scale 
 
Scale description 
 
The UHDRS (Huntington Disease Study Group, 1996) has been the most widely used scale 
for HD in routine clinical practice and clinical trials. The final version has four components 
assessing motor performance, cognitive performance, behavioral abnormalities and 
functional capacity. The motor section of the UHDRS includes 15 items, scored from 0 to 4 
and divided into six subdomains: oculomotor function, dysarthria, chorea, dystonia, gait, and 
postural stability (Huntington Disease Study Group, 1996). A teaching videotape showing 
how to assess the motor features is also available, helping to standardize the practical 
application of the scale, and to enhance inter-intra reliability. 
 
Key evaluation issues   
Internal consistency, in each of the four component, has shown high degree (Cronbach’s 
alpha values were 0.95 for the total motor score, 0.90 for the cognitive tests, 0.83 for the 
behavioral scale, and 0.95 for the functional checklist). Correlation analysis has shown that 
four components of UHDRS were highly intercorrelated, except for the behavioral score; 
nevertheless higher mood subscale scores correlated with better motor performance, whereas 
higher psychosis and obsessive subscale scores correlated with lower functional scores. 
High degree of intrerrater reliability, assessed by intraclass coefficient, has shown (intraclass 
correlation coefficient was 0.94 for the total motor score, 0.82 for the chorea score and 0.62 
for the dystonia score). Despite its psychometric properties including internal consistency, 
inter-rater reliability and sensitivity to change are satisfactory, its length and load have been 
criticized (Martinez-Martin al, 2014). It has been shown that UHDRS is useful for tracking 
clinical changes longitudinally in patients with HD. 
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Strengths and weaknesses 
The UHDRS assesses relevant clinical domains of HD and was designed for repeated 
administrations during clinical research studies. The UHDRS may be particularly suitable to 
follow clinical changes in the setting of controlled trials of experimental interventions. The 
UHDRS yields several scores assessing the primary features of HD (motor, cognitive, 
behavioral) as well as the overall functional impact of these features. 
 
 
Abnormal Involuntary Movement Scale 
 
Scale description 
 
The AIMS is a 12-item clinician-rated instrument to assess the severity of abnormal 
movements. Seven items assess the abnormal movements in seven body areas (Guy, 1976), 
each area scored from 0 to 4 (none, minimal, mild, moderate, severe). Three items rates the  
abnormal movements global severity and patient’s awareness, and the disability due to 
abnormal movements. Two more items focus on dental status. The scale includes specific 
instructions to standardize the evaluation and requires the examiner to observe the patient 
sitting quietly at rest and again while carrying out selected motor tasks.  
The severity rating is ranked one point lower when the abnormal movements occur only 
upon activation maneuvers (such as opening and closing mouth, finger tapping, standing or 
walking), then if they occur already (spontaneously) at rest at the same intensity.   
Key evaluation issues   
 
 AIMS meets the criterion to  use in HD and has been used by  several authors studying 
effects of different drugs on dyskinesia associated with HD (Guy, 1976; Vitale et al, 2007; 
Ondo et al, 2002; Van Vugt et al, 1997; De Tommaso, 2007). Clinimetric data rely mainly 
on the high inter-rater and test-retest reliability assessed in tardive dyskinesia (Seet et al. 
1993; Whall et al, 1983). The clinimetric properties of the scale have not been specifically 
examined in HD. Moreover, only the original version of the scale has been clinimetrically 
assessed, whereas none of the modified versions has undergone validation testing.  As a 
final designation, the AIMS meets the criteria of a Recommended scale, but with limitations 
that includes limited clinimetric data in HD patients, poor documentation of 
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phenomenological sub-types of dyskinesia, and no information on the impact of dyskinesia 
on the patient’s quality of life. 
 
Strengths and weaknesses 
The AIMS is quick to administer and takes only about 10 minutes to complete. It has been 
developed for tardive dyskinesia, therefore emphasizes face and neck abnormal movements 
that may not be the (only) primary focus of dyskinesia in HD. It focuses on dyskinesia 
localization (anatomy) but does not specified whether dyskinesia is dystonic or choreic. 
Moreover, the disability rating relies only on clinician’s judgement and does not account for 
patient’s perception. AIMS has several modified versions and it is not entirely clear whether 
clinimetric analyses are uniform across all versions. 
 
Modified Motor Score of the Unified Huntington’s Disease rating Scale 
Scale description 
The mMS is a subscale of the UHDRS Motor Score proposed by NeuroSearch (Waters et al. 
2010) which excluded eyes movements, chorea and dystonia and focused only on voluntary 
movements which correlate strongly with the disability related to HD compared to chorea.  
It has been proposed with the aim to have a quicker method to assess the response to 
treatment in patients with HD.  
Key evaluation issues   
The mMS has been applied in two clinical trial to investigate the potential effect of 
pridopidine in HD, the MermaidHD (Multinational European Study) and HART studies 
(which involves U.S. and Canada) (De Yebenes et al, 2011; HSG HART Investigators, 
2013). This subscale has shown improved internal consistency compared with total motor 
score (TMS), and interclass correlation similar to that for TMS, indicating good test-retest 
reliability(Waters et al. 2010).  
Strengths and weaknesses 
This subscale is brief and easy to perform and allows to monitor functional modifications 
over time, which are related to the disability due to worsening of the voluntary movements. 
However, the clinimetric properties have not been formally assessed, and  therefore this brief 
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scale reaches the Recommended status carrying several limitations.  
 
Tics 
Fourteen scales have been assessed for tic evaluation (Gadow & Paolicelli, 1986;  Walkup et 
al, 1992; Gaffney et al, 1994; Woods et al, 2005; Shapiro & Shapiro, 1984; Shapiro et al, 
1988; Shytle et al, 2003; Leckman et al, 1988; Leckman et al, 1989; Harcherik et al, 1984;  
Nolan et al, 1994; Storch et al, 2007; Cavanna et al, 2008; Jagger et al, 1982; Kompoliti et 
al, 1997; Kurlan et al, 1988) (Table 7), and twelve of them, the Global Tics Rating Scale 
(GTRS), the Hopkins Motor and Vocal Tic Scale (HMVTS), the Motor Tic, Obsessions and 
Compulsions, Vocal Tic Evaluation Survey(MOVES), the, the Premonitory Urge for Tics 
Scale (PUTS), the Shapiro Tourette Syndrome Severity Scale (STSSS), the Tourette’s 
Disorder Scale (TODS), the Tourette Syndrome-Clinical Global Impression (TS-CGI), the 
Tourette Syndrome Global Scale (TSGS), the Unified Tic Rating Scale (UTRS), the Gilles 
de la Tourette Syndrome Quality of Life (GTS-QoL) scale, the Yale Global Tic Severity 
Scale (YGTSS) and the Diagnostic Confidence Index (DCI), reached the recommendation 
status (Cavanna and Piedad, 2013) (Table 8). We describe below only the rating scales used 
in the evaluation of motor tics, whereas the GTS-QOL (Cavanna et al, 2008) and the DCI 
(Robertson et al, 1999) focus on health-related quality of life and clinician’s confidence in 
the diagnosis of Tourette syndrome, respectively. 
 
Global Tics Rating Scale 
Scale description 
The GTRS is a brief clinician-rated measure of tic frequency (Gadow & Paolicelli, 1986). 
This checklist contains nine items, with the first five referring to the frequency of motor 
(three items) and phonic tics (two items) according to body region, which are summed to 
produce motor and phonic tic frequency subscores, respectively. All items are rated on a 
scale from 0 (never) to 3 (very much).  
 Key evaluation issues   
When compared with other scales (YGTSS and GTRS) showed relatively small correlation 
coefficients (.01–.42), suggesting poor concurrent validity. Reliability appeared acceptable 
for motor and severity subscales with correlation coefficients of above .77, but less so with 
the vocal tic subscale (.58) (Nolan et al, 1994).  
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Strengths and weaknesses 
The GTRS has been used in interventional trials for patients with Tourette syndrome 
(Pringsheim & Steeves, 2011). It should be noted that, in the study by Nolan et al. (1994) the 
GTRS was rated by teachers, who may not have the experience of skilled clinicians in 
adequately recognizing tics. 
 
The Hopkins Motor and Vocal Tic Scale  
Scale description 
The HMVTS is a parent- and clinician-rated scale that measures motor and phonic tics using 
a visual analog scale (VAS) (Walkup et al, 1992). Each tic is given a rating from 0 (not 
present) to 10 (most severe), with four intermediate ratings: “mild,” “moderate,” 
“moderately severe,” and “severe.” The severity of tics is rated across their frequency, 
intensity, and the level of interference and impairment they cause. An overall score is also 
assigned to each motor or phonic tic, ranging from 1 (no tic symptoms) to 5 (worst ever).  
 Key evaluation issues   
Initial psychometric testing demonstrated excellent reliability and validity indices when 
compared to the YGTSS, STSSS, and behavioral measures (Walkup et al, 1992).  
Strengths and weaknesses 
The HMVTS has been used in intervention studies to assess tic symptoms (Pringsheim & 
Steeves, 2011; Singer et al, 1995). 
 
Motor Tic, Obsessions and Compulsions, Vocal Tic Evaluation Survey  
 
Scale description 
 
The MOVES is a self-report assessment of motor and phonic tics, associated phenomena, 
obsessions, and compulsions (Gaffney et al, 1994). These scores can be combined to 
produce tic or obsessive-compulsive subscores. Individuals are asked to rate the presence of 
their symptoms from a list of 20 items in the previous 4 weeks, on a 4-point scale from 
“never” to “always.”  
 
 Key evaluation issues   
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There are some issues with regard to its reliability, however, with some subscales showing 
below standard correlation coefficients (<.70): tic (.54), associated symptoms (.40), and total 
scores (.69) (Gaffney et al, 1994).  
 
Strengths and weaknesses 
The MOVES is a relatively straightforward scale. Its acceptable validity was demonstrated 
with strong correlations to two clinician-rated tic scales and two OCB measures, with some 
sensitivity to clinically relevant changes (Gaffney et al, 1994). Nevertheless, the MOVES is 
a useful adjunct to clinician ratings as a measure of patient perception of tic symptoms, for 
example during interventional or phenomenological studies ( addad et al, 2009; Mu nchau 
et al, 2002; Orth et al, 2005). 
 
Premonitory Urge for Tics Scale  
 
Scale description 
 
The PUTS is a relatively brief scale designed to examine the phenomenon of premonitory 
sensations (also called premonitory urges or sensory tics) in tic disorders (Woods et al, 
2005). It contains 10 descriptions of somatic sensations derived from phenomenological 
descriptions from the literature and clinical experience. The severity of urges is rated on a 4-
point ordinal scale ranging from 1 (not at all true) to 4 (very much true). Although 
psychometric properties appear acceptable in older pediatric patients, initial testing revealed 
inadequate properties for patients younger than 10 years (Woods et al, 2005).  
 
Recommendation status 
 
A direct translation in Hebrew has recently become available in a study that provided 
independent testing of the PUTS, showing adequate properties in patients older than 10 
years (Steinberg et al, 2010). Despite testing in pediatric populations only, adequate 
psychometric properties for older children may indicate utility in adults also. More recently, 
a study using the PUTS and a similar scale (USP-SPS, see below) demonstrated concurrent 
and discriminant validity (Sutherland Owens et al, 2011). 
 
Strengths and weaknesses 
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Despite testing in pediatric populations only, adequate psychometric properties for older 
children may indicate utility in adults also. 
 
 
Shapiro Tourette Syndrome Severity Scale  
 
Scale description 
 
The STSSS was developed to measure changes in tic symptoms during a clinical trial of 
pimozide (Shapiro & Shapiro, 1984; Shapiro et al, 1988). This clinician-rated scale 
addresses five factors: whether tics are noticeable, whether they elicit comments or 
curiosity, whether the patient is considered odd or bizarre, whether tics interfere with 
functioning, and whether they lead to incapacitation or to the patient being homebound or 
hospitalized. The item scores can be summed to produce total ratings, which are assigned a 
global severity rating on a 6-point scale from 0 (no tics) to 6 (very severe, total sum of 
ratings >8).  
 
 Key evaluation issues   
 
When compared with two measures of tic severity, the STSSS showed excellent reliability 
and validity (Walkup et al, 1992) and has been successfully used in interventional studies for 
Tourette syndrome (e.g., Mu ller-Vahl et al, 2002; Pringsheim & Marras, 2009; Pringsheim 
& Steeves, 2011) 
 
Strengths and weaknesses 
 
The STSSS take around 5 to 10 minutes to complete. However, the focus is clearly on social 
impairment, which somewhat limits the overall accurateness of this clinical assessment of 
tics. 
 
Tourette’s Disorder Scale  
Scale description 
 
The TODS is an objective measure of the severity of tics plus a wide range of 
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neuropsychiatric symptoms associated with Tourette syndrome over a period of 1 month 
(Shytle et al, 2003). The 15-items scale contains questions about tics, inattention, 
hyperactivity, obsessions, compulsions, aggressions, and emotional symptoms.  
 
 Key evaluation issues   
 
Clinician and parent-rated versions are available, both of which have been validated by 
further psychometric testing (Storch et al, 2007; Storch et al, 2004). 
 
Strengths and weaknesses 
Clinician and parent-rated versions are available. 
 
 
Tourette Syndrome-Clinical Global Impression  
 
Scale description 
 
The CGI is a frequently used measure of disease severity. In preparation for a clinical trial in 
Tourette syndrome, three disease-specific versions of the CGI were developed (Leckman et 
al, 1988). These assess symptoms of Tourette syndrome, obsessive-compulsive disorder 
(OCD), and attention-deficit and hyperactivity disorder (ADHD), based on DSM-III 
diagnostic criteria. The TS-CGI consists of seven items corresponding with descriptions of 
no identifiable symptoms (normal) to incapacitating tics or a high level of functional 
impairment associated with behavioral symptoms (extremely severe).  
 
 Key evaluation issues   
 
The TS-CGI showed excellent reliability and validity indices when compared to the STSSS 
and YGTSS (Walkup et al, 1992) and has been used as an adjunctive clinician measure in 
interventional studies (Kwon et al, 2011; Pringsheim & Marras, 2009; Pringsheim & 
Steeves, 2011; Sallee et al, 1997). 
 
Strengths and weaknesses 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
Very useful in the assessment of both motor and non-motor symptoms across tic disorders. 
 
Tourette Syndrome Global Scale  
 
Scale description 
 
The TSGS is a clinician-rated measure of tics and social functioning in Tourette syndrome 
(Harcherik et al, 1984). The tic subscore measures simple and complex motor and phonic 
tics based on their frequency and resulting impairment. Frequency scores are rated on a scale 
of 0 to 5, with higher scores corresponding to higher tic frequencies. Impairment is 
measured on a scale of 1 to 5 based on how noticeable tics are and the resulting functional 
impairment. The social functioning subscore measures the level of functional impairment in 
behavioral conduct, motor restlessness, and school and learning or work and occupation 
problems (whichever is relevant). These are rated on a scale of 0 to 25 in increments of 5, 
with 0 indicating lack of issues in respective domains and 25 indicating severe functional 
impairment. The global measure of severity is calculated using both the tic and social 
functioning subscores.  
 
 Key evaluation issues   
 
However, in a pharmacological trial of ondansetron, the TSGS detected a significant 
symptomatic change whereas a gold standard for measuring tic symptoms did not find 
differences compared to placebo (p = .002 vs. .15, respectively; Toren et al, 2005), 
suggesting potential concurrent validity issues. 
 
Strengths and weaknesses 
 
The advantage of the TSGS is its comprehensiveness in measuring different tic 
characteristics, as well as its multidimensionality by combining assessments of tics and their 
effects on social functionality. However, the formula for deriving global scores is relatively 
complicated and potentially produces social functioning subscores that are 
disproportionately weighted to tic symptoms (Kompoliti & Goetz, 1997). The TSGS has 
proven to represent an useful instrument in interventional studies (e.g., Mu ller-Vahl et al, 
2002; Pringsheim & Marras et al, 2009; Sallee et al, 1997). 
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Unified Tic Rating Scale  
 
Scale description 
 
The UTRS contains subscales rated by patients and/or informants and clinicians, which are 
summed to indicate overall tic severity. A 2-minute tic count is also incorporated to measure 
motor and vocal tics during conversation with the patient. The subscales contain items on 
the anatomical distribution of tics, types, frequency, intensity, and level of interference and 
suppression. Measures of ADHD and OCD symptoms and global functioning are also 
included.  
 
 Key evaluation issues   
 
The 2-minute tic count component was used in a phenomenological study in Tourette 
syndrome (Nolan et al, 1994), which demonstrated the versatility of the UTRS by focusing 
on relevant subscales. Revisions and piloting are currently under way, with a view toward 
improving the reliability, dimensionality, internal consistency, and validity (Kurlan & 
McDermott, 2005). 
 
Strengths and weaknesses 
 
The multidimensionality of the UTRS and the inclusion of both subjective and objective 
data are its greatest advantages. 
 
Yale Global Tic Severity Scale  
 
Scale description 
 
The YGTSS is the most widely used measure of tic severity in TS (Porta et al, 2009; 
Pringsheim et al, 2009; Pringsheim & Marras, 2009; Pringsheim & Steeves, 2011) and other 
tic disorders (Leckman et al, 1989). The YGTSS is based on a semistructured interview 
focusing on tic symptoms over the past week, where the clinician is asked to record patients’ 
motor and phonic tics. Subsequently, the tic symptoms are rated separately based on their 
number, frequency, intensity, complexity, and interference from 0 (no tic symptoms) to 5 
(severe). The tic severity subscore consists of the motor and phonic tic severity scores. This 
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is summed with the impairment subscore, which rates the severity of functional impairment 
from 0 to 50, to produce the total score (0–100).  
 
 Key evaluation issues   
 
The YGTSS allows a multidimensional overview of tic characteristics, as well as the level of 
functional interference.  The separation of motor and phonic tics is particularly useful, also 
for diagnostic purposes. Independent testing confirmed reliability and validity indices using 
the STSSS and TS-CGI (Walkup et al, 1992). A childhood and adolescent sample confirmed 
this scale’s excellent psychometric properties, particularly its internal consistency and 
validity (Storch et al, 2005). A factor analytic study also confirmed and validated the 
structure that was initially identified (Storch et al, 2007). Cutoff scores for clinically relevant 
treatment response have been proposed: a reduction by 35% in total YGTSS scores or 6 or 7 
points in the tic severity subscale (Storch et al, 2011).  
 
Strengths and weaknesses 
 
The YGTSS is an ideal instrument for busy routine clinical practice, as it takes only 15 
minutes to complete. 
 
Myoclonus 
 
Three scales have been assessed for myoclonus (Chadwick et al, 1977; Troung & Fahn, 
1988; Fructh et al, 2002; Table 9), but only one, the Unified Myoclonus Rating Scale 
UMRS) reached the recommendation status (Table 10). 
 
Unified Myoclonus Rating Scale 
 
Scale description 
 
This scale is a further development of the Truong and Fahn myoclonus scale (Truong & 
Fahn, 1988). The UMRS was modified to address some of the shortfalls from the original 
scale. The paper describing UMRS is published in a non peer reviewed book. (Frucht et al, 
2002). The UMRS is a quantitative 73-item clinical rating instrument developed to evaluate 
myoclonus and response, of patients with myoclonus, to anti-myoclonic therapy. The scale 
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contains a patient questionnaire, a handwriting and spiral sheet, rating instructions, a score 
sheets and a videotape. The scale consists of eight sections: section 1, patient questionnaire 
(11 items); section 2, myoclonus at rest (frequency and amplitude, 16 items); section 3, 
stimulus sensitivity of myoclonus (17 items); section 4, severity of myoclonus with action 
(frequency and amplitude, 20 items); section 5, performance on functional tests (5 items); 
section 6, physicians rating of patients global disability (1 item); section 7, presence of 
negative myoclonus (1 item); section 8, severity of negative myoclonus (1 item). Each item 
is rated on a scale of 0 to 4, with the exception of sections 3 and 7 (rated present or absent) 
and section 8 rated on a scale of 0-3.  
 
Key evaluation issues   
 
Members of the Myoclonus Study group performed statistical validation of the UMRS. 
Twenty patients with chronic myoclonus, having different etiologies and severity, were 
videotaped while UMRS was performed. Eighteen neurologists, experts in movement 
disorders, rated two tapes (ten patients per neurologist). A Cronbach’s alpha (measure of 
reliability) was calculated for each section of the UMRS and confirmed that the scale 
possesses excellent interrater reliability.  
 
Strengths and weaknesses 
 
The scale is easy to use and can be completed in less than 15 minutes. Intrarater reliability 
has not been tested formally (Frucht et al, 2002).  
 
 
Drug-induced dyskinesia 
 
Seven scales have been assessed for tardive dyskinesia (DID) evaluation (Simpson et al, 
1979; Sprague et al, 1984; Sprague et al, 1991;  Smith et al, 1983; Lund et al, 1991; Guy, 
1976; Chouinard and Margolese, 2005; Lindström et al, 2001) (Table 11). Only three of 
them received the recommendation status, the Simpson Tardive Dyskinesia Rating Scale 
(TDRS), the Abbreviated Dyskinesia Scale (ADS), the Dyskinesia Identification System – 
Coldwater (DIS-Co) 
Dyskinesia Identification System Condensed User Scale (DISCUS) and the Extrapyramidal 
Symptoms Rating Scale (ESRS) Extrapyramidal Symptoms Rating Scale abbreviated 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
version (ESRS-A) (table 12). The review of the scales used to measure L-Dopa induced 
dyskinesia in PD has been the focus of a specific article as part of the global effort to review 
all scales used in PD (Colosimo et al, 2010), and will not be further discussed here. 
 
TDRS: Simpson Tardive Dyskinesia Rating Scale 
ADS: Abbreviated Dyskinesia Scale  
 
Scale description   
 
The TDRS is a clinician-rated instrument to assess the severity of abnormal movements in 
four anatomical regions, each area scored from 0 to 6 (absent, possibly present, mild, 
moderate, moderately severe, very severe). Fourteen items rate the severity of abnormal 
movements in the facial region (including tongue and lips), six rate the neck/trunk region, 
six rate the upper limbs, six rate the lower limbs; two additional items rate the severity of 
abnormal movements involving the entire body. The scale includes specific instructions to 
standardize the evaluation. The highest severity of the abnormal movements is rated. The 
scale does not provide word-anchors to explain the designations of absent, minimal, mild, 
moderate and severe, so that these final designations may be biased by the rater’s 
experience. The scale was developed exclusively for rating tardive dyskinesia in psychiatric 
patients. Although it primarily focuses on anatomy, it characterizes movements using 
descriptive definitions of the various items, often referring also to phenomenological terms 
as ‘choreoathetoid’, ‘ballistic’, ‘torticollis’, and ‘tics’, suggesting it aims at encompassing 
different forms of hyperkinesias. There is no patient input into the ratings, relying on the 
clinician’s judgment rather than patient perceptions. Because it is a scale developed for 
tardive dyskinesia, it emphasizes face and neck movements that may not be the primary 
focus of dyskinesia in PD. The same group presented an abbreviated dyskinesia rating scale 
(ADS) consisting of only 13 items, characterised by a less focal reference to anatomical 
sites. Both scales offered the opportunity for raters to add additional individualized items 
(Simpson et al, 1979). 
 
Key evaluation issues   
 
Clinimetric data on TDRS and ADS rely mainly on inter-rater coefficients (0.98 and 0.97, 
respectively), whereas test-retest reliability has not been evaluated in detail. Convergent 
validity and responsiveness to change have also been evaluated. Given that this scale has 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
been applied to TD populations, that data on its use are available beyond the group that 
developed the scale, and that it showed good inter-rater reliability, convergent validity and 
responsiveness to change, both TDRS and ADS are considered Recommended for use in 
TD. 
 
Strengths and weaknesses 
 
The TDRS is quick to administer and takes about 15 minutes to complete. Intra-rater (test-
retest reliability) was not evaluated by authors.  
 
DIS-Co: Dyskinesia Identification System – Coldwater 
DISCUS: Dyskinesia Identification System Condensed User Scale 
 
Scale description 
 
The DIS-Co is a 34-item scale originally based on data from 519 “institutionalized mentally-
retarded residents”, 250 of whom had never received antipsychotic medications. The 34 
items are grouped in 10 body areas and scored on a five-point scale. Later, the scale was 
revised by the same authors, based on data collection from subsequent studies. They 
developed a method for selecting items for the rating scale based on six qualities, including 
interrater reliability, stability, and relationship with medication (Sprague et al, 1984, 
Sprague et al, 1991). 
 
Key evaluation issues   
 
The resulting 15-item scale, the DISCUS, has been used to assess tardive dyskinesia. Both 
have been thoroughly evaluated on psychometric properties: the DIS-Co showed 
0.78interrater reliability, 0.77 test-retest reliability (2-week stability), good construct and 
convergent validity, and good responsiveness to change; the DISCUS showed 0.92 interrater 
reliability and 0.40 2-week stability, based on 400 individuals with developmental disability 
(Sprague et al, 1991). 
 
Strengths and weaknesses 
 
This scale has been applied to TD populations, particularly those with developmental 
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disabilities, and it showed good inter-rater reliability, convergent validity and 
responsiveness to change. The limitation is the exclusive use in patients with learning 
disabilities. 
 
ESRS: Extrapyramidal Symptoms Rating Scale 
ESRS-A: Extrapyramidal Symptoms Rating Scale abbreviated version 
 
Scale description   
 
The ESRS is a clinician-rated instrument to assess the severity of parkinsonism, dyskinesia, 
dystonia and akathisia, each manifestation scored from 0 to 5 (absent, minimal, mild, 
moderate, severe, extreme) with welldefined explanatory word-anchors. Its most commonly 
used form (ESRS-A) comprises 28 items for the comprehensive evaluation of movement 
disorders. The scale includes specific instructions to standardize the evaluation. Ratings are 
made through a combination of clinical interview and motor examination, after which a 
score can be obtained. The severity of ratings should be related to both frequency and 
severity/intensity of the phenomenon being evaluated. The highest severity of the abnormal 
movements is rated. Each rating should represent the most appropriate rating based on 
overall clinical judgment for the anchor points pertaining to each symptom, with a temporal 
component considered secondarily (Chouinard and Margolese, 2005). 
 
Key evaluation issues   
 
Clinimetric data on ESRS rely mainly on inter-rater coefficients (0.86-0.91). Convergent 
validity and responsiveness to change have also been evaluated. During a cross-scale 
comparison, AIMS and ESRS were found to have a 96% agreement between TD-defined 
cases by DSM-IV TD criteria. This scale has been applied to TD populations, that data on its 
use are available beyond the group that developed the scale, and that it showed good inter-
rater reliability, convergent validity and responsiveness to change. 
 
Strengths and weaknesses 
 
The ESRS is quick to administer and takes about 15 minutes to complete. 
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Conclusions 
 
The adoption of valid rating scales for the assessment of patients with hyperkinetic disorders 
is needed to be able to share information, quantify health status and fully understand the 
trends and outcomes in clinical trials (Martinez-Martin et al, 2014). Although numerous 
scales aimed at assessing hyperkinetic disorders have been published, their variability in 
terms of clinimetric properties, availability and effort required to administer them is high. In 
this review, we identified scales defined as ‘Recommended’ for the assessment of all forms 
of hyperkinetic disorders. The situation highlighted by our systematic review nevertheless 
varies considerably, with several ‘Recommended’ scales being available for some conditions 
such as tics or dystonia, but only one being available for myoclonus. This gap needs to be 
filled by the scientific community through both the development of new clinical tools and 
the refinement of existing ones. Further work is also required to adapt and validate 
‘Recommended’ scales to specific patient populations according to different age groups and 
clinical stratifications. 
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Tables 
 
Table 1. Tremor: main characteristics of the scales assessed. 
 
Scale Time to 
complete 
Patient 
historical 
rating 
Clinical 
examination 
Administration 
burden 
FTM-TRS 15* 
 
 
yes yes 
 
 
 
± 
 
WHIGET 20* 
 
yes 
 
yes 
 
+ 
 
Bain TRS 10* no 
 
yes ± 
 
UTRA 10* 
 
yes 
 
yes 
 
+ 
 
TETRAS 10* 
 
yes 
 
yes 
 
+ 
 
VTSS 1* 
 
no 
 
yes 
 
+ 
 
Sweet et al. 
TRS 
5* 
 
no 
 
yes + 
 
 
Findley et al.  
TRS 
5* 
 
yes 
 
yes 
 
+ 
 
 
Koller et al. 
TRS 
5* 
 
no 
 
yes 
 
+ 
 
Jefferson et al. 
TRS 
5* 
 
yes 
 
yes 
 
± 
 
Baruzzi et al. 
TRS 
2* 
 
no 
 
yes + 
 
Ogawa et al. 
TRS 
2* yes yes 
 
+ 
 
Abbreviations: FTM-TRS, Fahn Tolosa Marin Tremor Rating Scale; WHIGET, Washington 
Heights-Inwood Genetic Study of Essential Tremor ; UTRA, Unified Tremor Rating 
Assessment; TETRAS, The Essential Tremor Rating Assessment Scale; VTSS, Vocal Tremor 
Scale Assessment. 
*mean estimated time to complete (not specified);  administration burden was rated as 
follows: ‘‘+’’(easy, e.g., summing up of the items), ‘‘±’’ (moderate, e.g., visual analogue 
scale (VAS) or simple formula), ‘‘-’’ (difficult, e.g., VAS in combination with formula, or 
complex formula).  
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Table 2. Tremor: classification of the scales assessed. 
 
Scale Applied in ET Applied 
beyond 
authors 
Successfull 
clinimetric 
testing 
Qualification 
FTM-TRS            yes yes yes 
 
 
Recommended 
 
WHIGET            yes yes 
 
yes 
 
Recommended 
 
Bain TRS            yes no 
 
yes Suggested 
 
UTRA            yes yes 
 
no 
 
Suggested 
 
TETRAS            no no 
 
yes 
 
Listed 
 
VTSS            no no 
 
yes 
 
Listed 
 
Sweet et al. 
TRS 
           yes no 
 
no 
 
Listed 
 
Findley et al.  
TRS 
           yes no 
 
no 
 
Listed 
 
Koller et al. 
TRS 
           yes no 
 
no 
 
Listed 
 
Jefferson et al. 
TRS 
           yes no 
 
no 
 
Listed 
 
Baruzzi et al. 
TRS 
           yes no 
 
no Listed 
 
Ogawa et al. 
TRS 
           yes no no 
 
Listed 
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Table 3. Dystonia: main characteristics of the scales assessed. 
 
Scale Time to 
complete 
Patient 
historical 
rating 
Clinical 
examination 
Administration burden 
BSDI n.a. yes no + 
Jankovic rating 
scale 
n.a. no yes + 
Blepharospasm 
Disability Scale 
4* yes yes + 
CDIP-58 n.a yes no + 
Functional 
Disability 
Questionnaire 
n.a. yes no + 
TWSTRS n.a no yes + 
Tsui scale n.a. no yes ± 
Modified Tsui 
scale 
 no yes + 
Freiberg 
Questionnaire for 
Dystonia torticollis 
version 
n.a. yes no ± 
Disability 
questionnaire for 
patients with 
cervical dystonia 
n.a. yes no + 
Body Concept 
Scale 
n.a. yes no - 
Ways of Coping 
Checklist 
n.a. yes no + 
CDQ-24 n.a. yes no + 
Oromandibular 
dystonia 
questionnaire 
n.a. yes no + 
Unified Spasmodic 
Dysphonia Rating 
Scale 
n.a. no yes + 
VHI n.a. yes yes + 
Voice Handicap 
Index 10 
n.a. yes no + 
Voice-Related 
Quality of Life 
n.a. yes no + 
VPQ n.a. yes no + 
Arm Dystonia <1* yes no ± 
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Disability Scale 
Dystonia 
Evaluation Scale 
<1* yes no + 
Tubiana-
Chamagne Score 
<1* yes no + 
Writer’s Cramp 
Rating Scale 
n.a. no yes ± 
Global Dystonia 
rating Scale 
n.a. no yes + 
FMDRS n.a. yes yes ± 
Unified Dystonia 
Rating Scale 
n.a. yes yes + 
 
 
 
 
 
Table 4. Dystonia: classification of the scales assessed. 
 
Scale Applied in 
Dystonia 
Applied 
beyond 
authors 
Succesfull 
clinometric 
testing 
Qualification 
BSDI yes yes yes Recommended 
Jankovic rating 
scale 
yes yes no Suggested 
Blepharospasm 
Disability Scale 
yes yes no Suggested 
CDIP-58 yes yes yes Recommended 
Functional 
Disability 
Questionnaire 
yes yes no Suggested 
TWSTRS yes yes yes Recommended 
Tsui scale yes yes no Suggested 
Modified Tsui scale yes no no Listed 
Freiberg 
Questionnaire for 
Dystonia torticollis 
version 
yes no no Listed 
Disability 
questionnaire for 
patients with 
cervical dystonia 
yes no no Listed 
Body Concept 
Scale 
yes no yes Suggested 
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Ways of Coping 
Checklist 
yes no no Listed 
CDQ-24 yes yes yes Recommended 
Oromandibular 
dystonia 
questionnaire 
yes no yes Suggested 
Unified Spasmodic 
Dysphonia Rating 
Scale 
yes yes no Suggested 
VHI yes yes yes Recommended 
Voice Handicap 
Index 10 
yes yes no Suggested 
Voice-Related 
Quality of Life 
yes yes no Suggested 
VPQ yes yes yes Recommended 
Arm Dystonia 
Disability Scale 
yes yes no Suggested 
Dystonia 
Evaluation Scale 
yes no no Listed 
Tubiana-
Chamagne Score 
yes yes no Suggested 
Writer’s Cramp 
Rating Scale 
yes yes no Suggested 
Global Dystonia 
rating Scale 
yes yes no Suggested 
FMDRS yes yes yes Recommended 
UDRS yes yes no Suggested 
 
Abbreviations: BSDI, Blepharospasm Disability Index; CDIP-58, Cervical Dystonia Impact 
Profile; TWSTRS, Toronto Western Spasmodic Torcicollis Rating Scale; CDQ-24, 
Craniocervical Dystonia Questionnaire; VHI, Voice Handicap Index; VPQ, Vocal 
Performance Questionnaire; FMDRS, Fahn-Marsden Dystonia Rating Scale, UDRS, 
Unified Dystonia Rating Scale. 
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Table 5. Chorea: main characteristics of the scales assessed. 
 
 
Scale Time to 
complete 
Patient 
historical rating 
Clinical 
examination 
Administration 
burden 
AIMS  10’ No Yes + 
Marsden & 
Quinn 
n.a. No Yes + 
UHDRS ≈ 30’ Semi-objective Yes + 
mMS brief No Yes + 
 
 
 
 
Table 6.  Chorea: classification of the scales assessed. 
 
Scale Applied in HD Applied beyond 
original authors  
Successful 
clinimetric 
testing 
Qualification 
UHDRS Yes Yes Yes Recommended 
AIMS Yes Yes Yes
a 
Recommended 
mMS Yes Yes No Recommended
b
 
Marsden & 
Quinn 
Yes Yes No Suggested 
 
Abbreviations:  UHDRS, Unified Huntington's Disease Rating Scale; 
a 
AIMS has several 
modified versions and it is not entirely clear whether clinimetric analyses are uniform 
across all versions. mMS,  modified motor score of the UHDRS 
b
With several limitations 
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Table 7. Tics: main characteristics of the scale assessed. 
 
Scale Respondent Administration 
time (minutes) 
Patient 
historic
al 
rating 
Clinical 
examination 
Administration 
burden
 
DCI Clinician n.a. Yes No + 
GTRS Informant, 
clinician 
n.a. No No + 
GTS-QoL Patient 10-15 No No ± 
HMVST Clinician 
(child/adolesce
nt, 
adult) 
n.a. No No ± 
MOVES Child/adolesce
nt, adult 
1-5 No No + 
PUTS Child (>10 
years)/ 
adolescent, 
Adults 
5 No No + 
STSSS Clinician 5-10 No No + 
TODS Informant 
(parent), 
clinician 
(child/adolesce
nt) 
5 No No + 
TS-CGI Clinician n.a. Yes No + 
TSGS Clinician 
(child/adolesce
nt, 
adult) 
n.a. Yes No ± 
TSQ Child/adolesce
nt, adult 
n.a. Yes No + 
TSSL Patient, 
informant 
n.a. Yes No + 
UTRS Clinician n.a.  No + 
YGTSS Clinician 
(child/adolesce
nt, 
adult) 
15-20 Yes No + 
Abbreviations: DCI, Diagnostic Confidence Index; GTRS, Global Tic Rating Scale; GTS-
QoL, Gilles de la Tourette Syndrome Quality of Life scale; HMVST, The Hopkins Motor and 
Vocal Tic Scale; MOVES, Motor Tic, Obsessions and Compulsions, Vocal Tic Evaluation 
Survey; PUTS, Premonitory Urge Tics Scale; STSSS, Shapiro Tourette Syndrome Severity 
Scale; TODS, Tourette’s Disorder Scale; TS-CGI, Tourette Syndrome Global Clinical 
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Impression; TSGS, Tourette Syndrome Global Scale; TSQ, Tourette Syndrome 
Questionnaire; TSSL, Tourette Syndrome Symptom List; UTRS, Unified Tic Rating Scale; 
YGTSS, Yale Global Tic Severity Scale. 
 
 
Table 8. Tics: classification of the scales assessed. 
 
Scale Applied in 
TS 
Applied beyond 
original 
authors 
Successful 
clinimetric 
testing 
Qualificationj
n 
DCI Yes Yes Yes Recommended 
GTRS Yes Yes Yes Recommended 
GTS-QoL Yes Yes Yes Recommended 
HMVST Yes Yes Yes Recommended 
MOVES Yes Yes Yes Recommended 
PUTS Yes Yes Yes Recommended 
STSSS Yes Yes Yes Recommended 
TODS Yes Yes Yes Recommended 
TS-CGI Yes Yes Yes Recommended 
TSGS Yes Yes Yes Recommended 
TSQ Yes Yes No Suggested 
TSSL Yes Yes No Suggested 
UTRS Yes Yes Yes Recommended 
YGTSS Yes Yes Yes Recommended 
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Table 9. Myoclonus: main characteristics of the scales assessed. 
 
Scale Time to complete 
(minutes) 
Patient 
historical 
rating 
Clinical 
examination 
 
Administration 
burden 
Chadwick & 
Marsden 
         ?          no            yes           ? 
Truong & 
Fahn 
             ?         no            yes           ? 
UMRS 15 minutes          yes            yes            + 
Abbreviations: UMRS, Unified Myoclonus Rating Scale. 
 
 
 
Table 10. Myoclonus: classification of the scales assessed. 
 
Scale Applied in 
myoclonus 
Applied beyond 
authors 
Successful 
clinimetric 
testing 
Qualification 
Chadwick & 
Marsden 
x x          0 suggested 
Troung & 
Fahn 
x x           0 suggested 
UMRS x x           x recommended 
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Table 11. DID: main characteristics of the scales assessed. 
 
Scale Time to 
complete 
(minutes) 
Patient historical 
rating 
Clinical 
examination 
Administration 
burden# 
AIMS 15 No Yes + 
TDRS/ADS 15-20/10-15 No Yes + 
DIS-co/DISCUS 20/15 No Yes + 
ESRS/ESRS-A 20*/10* No Yes + 
Smith Tardive 
Dyskinesia Scale 
15-20* No Yes + 
Modified Rogers 
Scale 
10 No Yes + 
UKU-SERS 10-30* Yes (patient 
version also 
available) 
Yes + 
 
Abbreviations: AIMS, Abnormal Involuntary Movement Scale; TDRS, (Simpson) Tardive 
Dyskinesia Rating Scale; MDS-UPDRS, revised version of the UPDRS; ADS, Abbreviated 
Dyskinesia Scale; DIS-Co, Dyskinesia Identification System-Coldwater; DISCUS, 
Dyskinesia Identification System Condensed User Scale; UKU-SERS, UKU-Side Effect 
Rating Scale 
 
 
 
 
Table 12. DID: classification of the scales assessed. 
 
Scale Applied in 
DID 
Applied beyond 
original authors 
Successful 
clinimetric testing 
Qualification 
AIMS X X X
a
 Recommended 
TDRS/ADS X X 0
b
 Suggested 
DIS-co/DISCUS X X X Recommended
 c
 
ESRS/ESRS-A X X X Recommended 
Smith Tardive 
Dyskinesia Scale 
X 0 0
 b
 Suggested 
Modified Rogers 
Scale 
X 0 unclear Listed 
UKU-SERS X 0 X Suggested 
a
Has several modified versions and it is not entirely clear whether clinimetric analyses are 
uniform across all versions.  
b
 Intra-rater (test-retest) reliability not evaluated by authors; construct validity not assessed 
c 
Used only in patients with learning disabilities 
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Highlights 
 
 Hyperkinetic disorders represent a heterogeneous group of conditions in which 
involuntary movements are the prevalent clinical symptoms. They include tremor, 
dystonia, tics, myoclonus and drug-induced dyskinesia 
 
 Good rating instruments for hyperkinetic disorders are required in both everyday 
practice and experimental settings  
 
 Unfortunately, the evaluation of these disorders is complicated by the inherent nature 
and variability over time of involuntary movements 
 
 On the basis of the methodology developed by the MDS task force for rating scales, 
a scale was defined as ‘Recommended’, ‘Suggested’ or ‘Listed’ in decreasing order 
of value 
 
 We identified scales defined as ‘Recommended’ for the assessment of all 
hyperkinetic disorders, with several ‘Recommended’ scales being available for  
conditions such as tics or dystonia, but only one for myoclonus  
